Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

269
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
269
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Isopropyl 3-(3,4-Dihydroxyphenyl)-2-Hydroxypropanoate Attenuates Experimental Renal Ischemia-Reperfusion Injury by Limiting Sterile Inflammation and Preserving Mitochondrial Function: Involvement of an Nrf2-Associated Cytoprotective Response.

Journal of inflammation research·2026
Same author

Synergistic regulation of iron cycle and hydroxyl radical generation in sodium percarbonate-based Fenton reaction enables efficient degradation of chlorinated hydrocarbons.

Journal of hazardous materials·2026
Same author

A Quantum Self-Attention Neural Network Model on Quantum Circuits.

IEEE transactions on cybernetics·2026
Same author

Construction of phosphorus and cobalt co-modified tubular carbon nitride with dual reaction sites for boosted imidacloprid degradation.

Journal of colloid and interface science·2026
Same author

Latent profile analysis of digital health literacy among community-dwelling older adults and its influencing factors.

Digital health·2026
Same author

Four-dimensional left ventricular motion clustering reveals cardiovascular phenotypes at population scale.

Scientific reports·2026

Related Experiment Video

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Drug Development.

Manuela Polydoro1, Ivana Geric2, Jin Zheng1

  • 1Muna Therapeutics, Copenhagen, Capital Region, Denmark.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
PubMed
Summary

MTX46943, a novel TREM2 agonist, activates microglia and reduces Alzheimer's Disease pathology by stabilizing the TREM2/DAP12 complex. This small molecule therapy shows potential for early AD treatment.

More Related Videos

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

Related Experiment Videos

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Microglia are key innate immune cells in the brain, crucial for maintaining health and resolving Alzheimer's Disease (AD) pathology.
  • TREM2 (Triggering Receptor Expressed on Myeloid cells 2) is a receptor that modulates microglia responses to misfolded proteins, essential for neuronal function.
  • MTX46943 is a novel, potent, selective, safe, and brain-penetrant small molecule agonist targeting TREM2 for early AD treatment.

Purpose of the Study:

  • To investigate the mechanism of action and efficacy of MTX46943, a TREM2 agonist, in activating microglia and reducing AD pathology.
  • To characterize the downstream effects of MTX46943 on TREM2 receptor complex dynamics and microglia function.
  • To evaluate the in vivo impact of chronic MTX46943 treatment on amyloid pathology in a mouse model of AD.

Main Methods:

  • In vitro assays (nanoBiT, Western blot, alphaLISA, migration, phagocytosis) were used to assess TREM2 activation and downstream effects in various cell types.
  • Comparison of MTX46943 with TREM2 agonist antibodies to differentiate receptor activation modalities.
  • In vivo studies involved chronic treatment of 5xFAD // hTREM2 knock-in mice, followed by analysis of microglia and brain tissue using qPCR, single-cell RNA sequencing, and immunostaining.

Main Results:

  • MTX46943 promotes TREM2/DAP12 receptor complex formation and stabilizes its surface presence, crucial for microglia activation, distinct from antibody agonists.
  • In vivo, MTX46943 treatment reprogrammed microglia in the presence of amyloid pathology, leading to a significant reduction in neurotoxic amyloid beta species.
  • Observed effects in vivo were consistent with MTX46943's in vitro potency at brain-penetrant exposure levels.

Conclusions:

  • MTX46943, a selective TREM2 agonist, is advancing to clinical studies for early Alzheimer's Disease treatment.
  • The study demonstrates MTX46943's differentiated mechanism involving TREM2 receptor complex stabilization and microglia reprogramming.
  • Chronic MTX46943 treatment significantly reduces brain amyloid pathology and supports its potential as a best-in-class therapy for AD.